0000902664-20-002288.txt : 20200604
0000902664-20-002288.hdr.sgml : 20200604
20200604172548
ACCESSION NUMBER: 0000902664-20-002288
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200602
FILED AS OF DATE: 20200604
DATE AS OF CHANGE: 20200604
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: JOHNSON DAVID EDWARD
CENTRAL INDEX KEY: 0001785557
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-10865
FILM NUMBER: 20943806
MAIL ADDRESS:
STREET 1: 520 MADISON AVENUE
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMAG PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000792977
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 042742593
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1100 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 6174983300
MAIL ADDRESS:
STREET 1: 1100 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: AMAG PHARMACEUTICALS INC.
DATE OF NAME CHANGE: 20070724
FORMER COMPANY:
FORMER CONFORMED NAME: ADVANCED MAGNETICS INC
DATE OF NAME CHANGE: 19920703
4
1
ownership.xml
X0306
4
2020-06-02
0
0000792977
AMAG PHARMACEUTICALS, INC.
AMAG
0001785557
JOHNSON DAVID EDWARD
520 MADISON AVENUE
NEW YORK
NY
10022
1
0
1
0
Common Stock, par value $0.01 per share ("Common Stock")
2020-06-02
4
A
0
10269
A
14676
D
Common Stock
3499428
I
See footnote
Stock Option (Right to Buy)
8.52
2020-06-02
4
A
0
21289
A
2030-06-02
Common Stock
21289
21289
D
Each restricted stock unit represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). These shares of Common Stock are issuable pursuant to a grant of restricted stock units pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan") that will vest in twelve equal monthly installments beginning on July 1, 2020; however, delivery of the shares is deferred until the earlier of (a) a Change in Control (as defined in the Issuer's Non-Employee Directors' Deferred Compensation Program) of the Issuer and (b) the date of the director's separation from service to the Issuer.
Not applicable.
Such securities are held by an affiliated fund and managed account to which Caligan Partners LP ("Caligan") serves as investment manager. David Johnson is the Partner of Caligan and Managing Member of Caligan Partners GP LLC, the general partner of Caligan.
Grant of stock option pursuant to the Plan. This option will vest and become exercisable in twelve equal monthly installments commencing July 1, 2020.
Remarks: Mr. Johnson disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that Mr. Johnson is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
/s/ David Johnson
2020-06-04